“…In addition GR231118, a homodimeric peptide based on the C-terminal sequence of NPY [(Ile, Glu,Pro,Dpr,Tyr,Arg,Leu,Arg,Try-NH 2 )-2-cyclic(2,4Ј),(2Ј,4)-diamide, also known as 1229U91] was originally identified as a competitive Y 1 receptor antagonist with low Y 2 affinity (Daniels et al, 1995;Hegde et al, 1995), but this dimeric nonapeptide also has Y 4 affinity and efficacy (Matthews et al, 1997;Parker et al, 1998;Schober et al, 1998Schober et al, , 2000. The recent generation of Y 4 knockout ( Ϫ/Ϫ ) mice provides the only current alternative to explore the loss of specific function associated with obesity (Sainsbury et al, 2002), cardiac function (Smith-White et al, 2002), and water intake (Wultsch et al, 2006). These studies found that Y 4 Ϫ/Ϫ mice are leaner, have decreased resting heart rate with lower arterial blood pressure, and increased dark phase water intake compared with wild-type (WT) mice.…”